Home > Search Results

Results: 2

Interferon alpha for patients with chronic hepatitis D

Hepatitis D virus is unique in that it can only infect a person who is already infected by hepatitis B virus. Chronic hepatitis D is a difficult‐to‐treat infection. Several antiviral and immunomodulating agents have been evaluated in treatment of hepatitis D. However, with the exception of interferon, all of them proved ineffective. This meta analysis of six randomised clinical trials of interferon shows that even Interferon alpha is not an ideal drug for this infection. Among the 169 participants included in primary meta analysis, interferon alpha induced loss of virus, normalisation of liver tests, and improvement in the liver biopsy in more patients compared with those who were left untreated. Unfortunately, most of these patients did not have sustained response after stopping treatment. Additional analysis of two trials comparing a higher dose of interferon alpha with lower dose among randomly assigned participants showed no significant difference in outcome between the two groups. There were differences in dosage and duration of interferon alpha used among included trials as well as some other methodological weakness which places a high risk of bias in this meta analysis.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2012

Evidence supporting colchicine for alcoholic, viral, and cryptogenic liver fibrosis/cirrhosis is still lacking

Alcohol and hepatotropic viruses are major causes of liver fibrosis and liver cirrhosis. Colchicine is an anti‐inflammatory and anti‐fibrotic drug. This systematic review could not demonstrate any significant beneficial effects of colchicine on mortality, liver‐related mortality, liver complications, liver biochemistry, or liver histology of patients with liver fibrosis or liver cirrhosis due to alcohol, hepatitis B, hepatitis C, or unknown etiology. Colchicine was associated with a significant increase in adverse events. Accordingly, there seems to be no evidence for using colchicine for alcoholic, viral, or cryptogenic liver fibrosis/cirrhosis outside randomised clinical trials.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2009

Systematic Reviews in PubMed

See all (300)...

Recent Activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...